|
City of Hope |
|
Adaptimmune |
Cancer - Lung |
A Phase I/ II Dose Escalation Open Label Clinical Trial Evaluating the Safety and Efficacy of MAGE A10ᶜ⁷⁹⁶T in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC) |
Active, not recruiting |
|
|
City of Hope |
|
Adaptimmune |
Cancer - Myeloma |
NY-ESO-1ᶜ²⁵⁹T Alone and in Combination With Pembrolizumab for Multiple Myeloma |
Recruiting |
|
|
City of Hope |
|
Adaptimmune |
Cancer - Lung |
A Phase I/II Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC) |
Recruiting |
|
|
City of Hope |
|
Adaptimmune |
Cancer - Lung |
Screening Protocol for Tumor Antigen Expression and HLA Sub-Type in NSCLC |
Recruiting |
|
|
City of Hope |
|
Adaptimmune |
Cancer - Ovarian |
A Phase I/IIa, Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Patients With Recurrent or Treatment Refractory Ovarian Cancer. |
Recruiting |
|
|
City of Hope |
|
Adaptimmune |
Cancer - Sarcoma |
A Pilot Study of Genetically Engineered NY-ESO-1 Specific (c259) T Cells in HLA-A2+ Patients With Synovial Sarcoma |
Active, not recruiting |
|
UCI
& UCSD & UC Davis |
|
Aivita Biomedical |
Cancer - Brain |
Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma |
Recruiting |
|
|
City of Hope |
|
Angiocrine Bioscience |
Cancer - Leukemia |
A Phase 1B, Open Label, Multi-Center Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation |
Recruiting |
|
|
UCSD |
|
Asterias Biotherapeutics |
Spinal Cord Injury |
Dose Escalation Study of AST-OPC1 in Spinal Cord Injury |
No longer active |
|
|
UC Davis |
|
Atara Bio. |
EBV-PTLD |
Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study) |
Recruiting |
|
|
City of Hope |
|
Atara Bio. |
Cancer - Nasopharyngeal Carcinoma |
Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) |
Recruiting |
|
|
UCSF |
|
Bioverativ Therapeutics, Inc |
Sickle Cell Disease |
A Phase 1/2, Open-Label, Multicenter, Single-Arm Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients with Severe Sickle Cell Disease |
Recruiting |
|
|
UCSF |
|
bluebird bio |
Sickle Cell Disease |
A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in Severe Sickle Cell Disease |
Recruiting |
|
|
UCI |
|
BrainStorm Cell Therapeutics |
Amyotrophic Lateral Sclerosis (ALS) |
A phase 3, randomized, double-blind, placebo-controlled multicenter study to evaluate efficacy and safety of repeated administrations of NurOwn® (autologous mesenchymal stem cells secreting neurotrophic factors) in participants with ALS |
Recruiting |
|
|
UCLA |
|
Calimmune |
HIV/AIDS |
Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection |
No longer active |
|
|
UC Davis |
|
Capricor Therapeutics |
Muscle - Duchenne Muscular Dystrophy |
A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy (HOPE-2) |
Recruiting |
|
|
City of Hope |
|
Celgene |
Cancer - Lymphoma |
An Exploratory Phase 1/2 Trial to Evaluate the Safety and Efficacy of JCAR017 Combinations in Subjects with Relapsed/Refractory B-Cell Malignancies (PLATFORM) |
Recruiting |
|
|
City of Hope |
|
Children's Hospital Los Angeles |
Infection After Stem Cell Transplant |
Antiviral Cellular Therapy for Enhancing T-cell Reconstitution |
Recruiting |
|
City of Hope
& UCLA |
|
City of Hope |
HIV/AIDS |
Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients |
Recruiting |
|
|
City of Hope |
|
City of Hope |
Cancer - Brain |
Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas |
Active, not recruiting |
|
|
City of Hope |
|
City of Hope |
Cancer - Brain |
Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma |
Recruiting |
|
|
City of Hope |
|
City of Hope |
Cancer - Brain |
Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas |
Recruiting |
|
|
City of Hope |
|
City of Hope |
Cancer - Lymphoma (AIDS-Related) |
Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma |
Active, not recruiting |
|
|
City of Hope |
|
City of Hope |
Sickle Cell Disease |
Safety of Blood Stem Cell Mobilization With Plerixafor in Patients With Sickle Cell Disease (PISMO) |
Recruiting |
|
|
City of Hope |
|
City of Hope |
Cancer - Brain |
Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma |
Recruiting |
|
|
City of Hope |
|
City of Hope |
Cancer - Brain |
HER2-CAR T Cells in Treating Participants With Brain or Leptomeningeal Metastases |
Recruiting |
|
|
City of Hope |
|
City of Hope |
Cancer - Leukemia |
Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia |
Recruiting |
|
|
City of Hope |
|
City of Hope |
Cancer - Prostate |
PSCA-CAR T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer |
Recruiting |
|
|
City of Hope |
|
City of Hope |
Sickle Cell Disease |
A Pilot Study to Evaluate the Safety and Feasibility of Induction of Mixed Chimerism in Sickle Cell Disease Patients with COH-MC-17: a Non-Myeloablative, Conditioning Regimen and CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant |
Recruiting |
|
|
City of Hope |
|
City of Hope |
Cancer - Lymphoma |
Angiocrine: HuVEC infusion post HCT in lymphoma (Budde) |
Recruiting |
|
|
City of Hope |
|
City of Hope |
Neurodegenerative Disorder |
Acquisition of Skin Biopsy Samples from Healthy Volunteers and Patients Diagnosed with X-Linked Adrenoleukodystrophy (ALD), Canavan Disease (CD) and other Inherited Leukodystrophies |
Recruiting |
|
|
UCSD |
|
Discgenics |
Degenerative Disc Disease |
Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Intervertebral Disc Degeneration |
Recruiting |
|
|
City of Hope |
|
Glaxo Smith Kline (GSK) |
Cancer - Lung |
Pilot Immunotherapy Study With Autologous T-cells Specific for New York Esophageal Antigen-1 (NY-ESO-1)/ Cancer-testis Antigen-2 (LAGE-1a)-Positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab |
Recruiting |
|
UCI
& UC Davis |
|
Humacyte |
Kidney Failure |
An Assessment of Humacyte's Human Acellular Vessel in Patients Needing Renal Replacement Therapy: A Comparison With ePTFE Grafts as Conduits for Hemodialysis (HUMANITY) |
Active, not recruiting |
|
UCI
& UC Davis |
|
Humacyte |
Kidney failure |
A Phase 3 Study to Compare the Efficacy and Safety of Humacyte's Human Acellular Vessel With That of an Autologous Arteriovenous Fistula in Subjects With End Stage Renal Disease |
Recruiting |
|
|
UCI |
|
ImmunoCellular Therapeutics |
Cancer - Brain |
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma |
No longer active |
|
|
City of Hope |
|
Janssen Research & Development, LLC. |
Cancer - Myeloma |
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma (CARTITUDE-1) |
Recruiting |
|
|
UCI |
|
jCyte |
Eye - Retinitis Pigmentosa (RP) |
Safety of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Retinitis Pigmentosa |
No longer active |
|
|
City of Hope |
|
Juno Therapeutics |
Cancer - Leukemia |
Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL) |
No longer active |
|
|
City of Hope |
|
Juno Therapeutics |
Cancer - Leukemia |
Long-Term Follow-up Study for Patients Previously Treated With JCAR015 |
No longer active |
|
|
City of Hope |
|
Juno Therapeutics |
Cancer - Myeloma |
Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma (EVOLVE) |
Recruiting |
|
|
City of Hope |
|
Juno Therapeutics |
Cancer - Lymphoma |
An Open-Label, Phase 1 Safety and Phase 2 Randomized Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004) |
Recruiting |
|
|
City of Hope |
|
Juno Therapeutics |
Cancer - Lymphoma |
Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (NHL) |
Recruiting |
|
|
City of Hope |
|
Kite Pharma |
Cancer - Lymphoma |
A Phase 1-2 Multi-Center Study Evaluating KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1) (ZUMA-1) |
Recruiting |
|
|
UC Davis |
|
Kite Pharma |
Advanced Cancer |
A Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects with Advanced Cancers |
Recruiting |
|
|
City of Hope |
|
Kite Pharma |
Cancer - Lymphoma |
Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma (ZUMA-12) |
Recruiting |
|
|
City of Hope |
Elizabeth Budde, MD
626-218-2405 |
Kite Pharma |
Cancer - Lymphoma |
A Multicenter, Open-label, Expanded Access Study of Axicabtagene Ciloleucel for the Treatment of Subjects With Relapsed/Refractory Large B-cell Lymphoma |
Recruiting |
|
|
City of Hope |
|
Kite Pharma |
Cancer - Lymphoma |
A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ZUMA-6) |
Recruiting |
|
|
City of Hope |
|
Kite Pharma |
Cancer - Lymphoma |
A Phase 2 Multicenter Study Evaluating Subjects With Relapsed/Refractory Mantle Cell Lymphoma (ZUMA-2) |
Active, not recruiting |
|
|
UCI |
|
Longeveron |
Aging frailty |
Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty |
Active, not recruiting |
|
